Paul van Damme
Director/Board Member at XORTX THERAPEUTICS INC.
Net worth: 18 415 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Allen Davidoff | M | 64 | 6 years | |
| Perry Dellelce | M | - |
ZipLocal, Inc.
 ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.
Bradmer Pharmaceuticals, Inc.
 Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada.
Wildlaw Capital Markets, Inc.
 Wildlaw Capital Markets, Inc. Investment ManagersFinance Wildlaw Capital Markets, Inc. provides investment advice. The private company is based in Toronto, Canada. | 8 years |
| Kevin Dane | M | - |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.
Wildlaw Capital Markets, Inc.
Wildlaw Capital Markets, Inc. Investment ManagersFinance Wildlaw Capital Markets, Inc. provides investment advice. The private company is based in Toronto, Canada. | 5 years |
| Miri Wernli | M | 71 | 4 years | |
| Jim Fairbairn | M | 65 | 5 years | |
| William Farley | M | 68 | 3 years | |
| Laurence Ezer | M | - |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | 8 years |
| Sheldon Inwentash | M | 68 |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | 12 years |
| Raymond Pratt | M | 73 | 3 years | |
| Anthony Giovinazzo | M | 67 | 2 years | |
| Stephen Haworth | M | - | 3 years | |
| Charlotte May | F | - | - | |
| David MacDonald | M | - | 2 years | |
| Brian Mangal | M | - | - | |
| Tyler Lang | M | 51 |
WD Capital Markets, Inc.
 WD Capital Markets, Inc. Finance/Rental/LeasingFinance WD Capital Markets, Inc. provides equity and debt financing services. The private company is based in Toronto, Canada. | 10 years |
| Patrick Treanor | M | - | 1 years | |
| Nick Rigopulos | M | - | - | |
| Stacy Evans | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| W. Rowlands | M | 62 | 6 years | |
| Scott M. Freeman | M | 67 | - | |
| Robert Tessarolo | M | 56 |
Bradmer Pharmaceuticals, Inc.
Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada. | - |
| Owen B. Menzel | M | - |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | 7 years |
| Harvey McKenzie | M | 78 | 2 years | |
| Jacqueline Le Saux | F | - | 2 years | |
| Elaine Kunda | F | 51 |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | 6 years |
| Helen Martin | F | 46 | 4 years | |
| Charles Lilly | M | - |
Bradmer Pharmaceuticals, Inc.
Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada. | 10 years |
| Jeffrey R. G. Jackson | M | - |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | - |
| Bruce G. Cousins | M | 63 | 2 years | |
| Raj Ravindran | M | 54 |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | - |
| Allan Williams | M | 66 | 3 years | |
| Mark C. Rogers | M | - |
Bradmer Pharmaceuticals, Inc.
Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada. | 4 years |
| John Albright | M | - |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | 3 years |
| Jukka Kalervo Karjalainen | M | - |
Bradmer Pharmaceuticals, Inc.
Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada. | - |
| Ian Klassen | M | 57 | 3 years | |
| Joseph Schmitt | M | - |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | 3 years |
| Susan McCormick | F | - | 4 years | |
| Marc Wade | M | - |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | 1 years |
| David G. Matthews | M | 62 | - | |
| Bin Huang | M | 65 | 6 years | |
| Carol Nast | F | 78 | - | |
| Donald Gehlert | M | - | 1 years | |
| Dave Guebert | M | 64 | 2 years | |
| Brian D. Brohman | M | - |
Bradmer Pharmaceuticals, Inc.
Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada. | - |
| Andrea B. Parker | M | - |
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 3 years |
| Ronald M. Cresswell | M | 89 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | - |
| Edward Miller | M | 81 |
Bradmer Pharmaceuticals, Inc.
Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada. | - |
| Michael Martin | M | 74 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | - |
| Gregory A. Curt | M | - | 1 years | |
| Donald William Kufe | M | 79 |
Bradmer Pharmaceuticals, Inc.
Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada. | 2 years |
| Paul Sparkes | M | 60 |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | 1 years |
| Timothy Gould | M | - |
ZipLocal, Inc.
ZipLocal, Inc. Financial ConglomeratesFinance ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada. | 7 years |
| Robert W. Rieder | M | 78 |
Bradmer Pharmaceuticals, Inc.
Bradmer Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada. | - |
| Bernard Lim | M | - |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 6 years |
| André Bérard | M | 83 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 6 years |
| Calvin Stiller | M | 83 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 3 years |
| Surya Mohapatra | M | 74 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | 4 years |
| Amar Keshri | M | 46 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 58 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul van Damme
- Personal Network
